A San Francisco biotech company called Loyal has developed a daily prescription pill designed to extend the healthy lifespan of senior dogs, and has now cleared two of three major regulatory hurdles required for FDA approval, with a market launch targeted for 2026.
At the same time, a separate research programme backed by the National Institutes of Health is running the largest clinical trial in veterinary history, testing a second drug’s ability to slow the aging process in companion dogs across the United States.
For dog owners, the implications of both programmes are profound.
For scientists studying the biology of aging, they are even more so.
How the Study Was Conducted
Loyal, founded six years ago by CEO Celine Halioua, has been building a pipeline of canine longevity drugs since the company’s earliest days.
The lead product is LOY-002, a daily beef-flavoured prescription pill targeted at senior dogs aged 10 years and older, weighing at least 14 pounds.
The drug aims to extend the healthy lifespan of senior dogs and maintain their quality of life as they age by proactively targeting the underlying metabolic drivers of aging and delaying the onset of disease.
The science behind it is rooted in a well-established biological mechanism called caloric restriction mimicry.
Decades of research across multiple species has shown that reducing caloric intake, without causing malnutrition, can dramatically extend lifespan by altering how cells process energy and manage growth signals.
Loyal’s pill is designed to produce those same cellular effects without requiring dogs, or their owners, to change what or how much they eat.
Studies have shown that caloric restriction can extend a dog’s lifespan, but restricting a pet’s food intake can be emotionally challenging for owners, which is why Loyal’s pill aims to mimic the metabolic benefits of caloric restriction without requiring dietary limitations.
The specific target of LOY-002 is a hormone called IGF-1, Insulin-Like Growth Factor 1, which plays a central role in cellular growth and metabolism throughout a dog’s life.
To test whether the drug works, Loyal launched the STAY study, a large-scale, placebo-controlled clinical trial that enrolled dogs at veterinary clinics across the United States, half of them receiving the actual LOY-002 pill and half receiving an identical beef-flavoured placebo.
The STAY study completed enrollment in July 2025 with 1,300 dogs across 70 veterinary clinics, making it the largest clinical trial in the history of veterinary medicine.
Findings From the Study
In January 2026, the FDA’s Center for Veterinary Medicine accepted Loyal’s Target Animal Safety submission for LOY-002, confirming that the drug is safe for its intended use in senior dogs.
This followed the FDA’s acceptance in February 2025 of the drug’s Reasonable Expectation of Effectiveness, a regulatory determination that the scientific evidence supports the drug’s ability to do what Loyal claims.
With both the Reasonable Expectation of Effectiveness and Target Animal Safety sections now complete, LOY-002 has earned FDA acceptance for two of three major technical sections required for market launch.
The safety data has been comprehensive.
The FDA reviewed field safety data from 400 dogs enrolled in the STAY study. The submission included information from dogs given LOY-002 for up to one year, and patients with a variety of ongoing medical conditions and other treatments commonly seen in senior dogs were included. The agency agreed that these data support the conclusion that LOY-002 is safe for its intended use.
No clinically significant adverse events were observed even at doses five times the intended strength.
Halioua responded to the safety milestone directly: “Since founding Loyal six years ago, my goal has always been to get the first drug FDA approved for lifespan extension. This safety acceptance brings us very close to achieving that vision.”
Why Large Dogs Age Faster and Die Sooner
To understand why this research matters so much for so many dogs, it helps to understand one of the most striking and counterintuitive facts in all of animal biology.
In most of the animal kingdom, bigger means longer-lived.
Elephants outlive mice.
Whales outlive elephants.
But within the dog species, the relationship is completely reversed.
A Chihuahua can live to 20.
A Great Dane is lucky to reach 8.
The reason appears to be IGF-1.
Selectively breeding large and giant breed dogs has resulted in them having levels of IGF-1 up to 28 times higher than those of small dogs.
This hormone drives rapid growth during puppyhood, allowing large breed dogs to reach their enormous adult sizes in the same developmental timeframe as small breeds.
But that same hormonal environment, persisting into adulthood and old age, appears to accelerate the aging process at a cellular level, driving dogs toward age-related disease, organ dysfunction, and death far earlier than their smaller counterparts.
Loyal’s LOY-002 targets this mechanism directly, aiming to reduce excess IGF-1 activity in older dogs and slow the biological clock that has been running too fast since birth.
A Second Drug Taking a Different Approach
Loyal is not the only team working on this problem, and the science being pursued in parallel takes a completely different angle.
The Dog Aging Project (DAP), a research collaboration between Texas A&M University and the University of Washington, is running its own clinical trial called TRIAD: the Test of Rapamycin in Aging Dogs.
Researchers led by Texas A&M have received $7 million from the National Institutes of Health to expand the clinical trial studying rapamycin’s ability to extend the lives of companion dogs.
Rapamycin is an existing drug, already approved for human use as an immunosuppressant following organ transplants.
But decades of laboratory research have suggested it has a second, remarkable property: the ability to extend lifespan.
Evidence from laboratory studies suggests that rapamycin can improve heart muscle function, cognitive function, and mobility, as well as extending lifespan.
It works by inhibiting a cellular pathway called mTOR, which regulates how cells respond to nutrients and energy availability.
Rapamycin works by modifying the cells’ energy balance and energy handling. It seems to mimic the effects that happen in people or animals who do intermittent fasting.
An early trial in healthy middle-aged dogs found that just 10 weeks of low-dose rapamycin produced measurable improvements in heart function, with trends toward better systolic and diastolic function compared to placebo-treated dogs.
The TRIAD trial is now testing whether those early signals translate into something more significant: actual lifespan extension, measured over years of real-world follow-up.
What Most People Get Wrong About Canine Aging Research
Here is where the story gets bigger than dogs.
Most people, when they hear about research into canine longevity, assume this is science conducted purely out of love for animals.
That is part of it.
But it is not the whole picture.
Dogs are, in a remarkable number of ways, the ideal model for studying human aging.
Unlike laboratory mice, which live in controlled environments, eat standardised diets, and never get stuck in traffic or stressed by a thunderstorm, dogs live in the human world.
They breathe the same air.
They eat similar foods, sometimes identical ones.
They develop many of the same age-related diseases humans do, including cancer, heart disease, kidney failure, arthritis, and cognitive decline resembling dementia.
And they do all of it on a compressed timescale.
The shorter life expectancy of dogs compared to human beings provides a unique opportunity for an accelerated timeline to test interventions that might extend healthy lifespan. The TRIAD randomised clinical trial represents the first rigorous test of a pharmacologic intervention against biological aging with lifespan and healthspan metrics as endpoints to be performed outside of the laboratory in any species.
A human clinical trial for a longevity drug would need to run for decades before researchers could collect meaningful data on whether it actually extended life.
A canine trial can generate the same quality of evidence in a fraction of the time.
Every dog enrolled in TRIAD or the STAY study is not just a beloved family pet receiving a potentially life-changing treatment.
It is also a data point contributing to a scientific understanding of aging that could eventually translate into treatments for the humans who love them.
Dogs experience many of the age-related cognitive, sensory, neuropathologic, and mobility changes that are common in older humans. This similarity makes research into canine health mutually beneficial: we get to learn how to support both dog and human aging at the same time.
A Pipeline of Longevity Drugs
LOY-002 is not Loyal’s only product in development.
The company has a broader pipeline designed to address the different aging dynamics of dogs of different sizes.
LOY-001 is an injection-based treatment aimed specifically at large and giant breed dogs aged seven and older, targeting the same IGF-1 pathway but through a different delivery mechanism.
A third longevity drug, LOY-003, is also in Loyal’s pipeline. LOY-003 is a prescription pill that aims to provide the same benefits to the large and giant breed canine population as LOY-001.
If these drugs reach the market as planned, it will represent the first time any species has had access to an FDA-approved pharmaceutical specifically designed to extend lifespan rather than simply treat a specific disease.
That distinction matters enormously.
Most drugs approved by the FDA address a defined illness.
They treat cancer, or infection, or organ failure.
What Loyal is attempting to do is treat aging itself as the underlying condition, targeting the biological processes that make every other age-related disease possible.
If it works in dogs, the ramifications for human medicine are significant.
What This Means for Dog Owners Right Now
LOY-002 is not yet available to prescribe.
Loyal still has one final major technical section to complete before it can apply for the FDA’s expanded conditional approval, a regulatory pathway designed to allow innovative veterinary therapies to reach the market while their full clinical trials continue.
Loyal expects to complete the final major technical section and apply for expanded conditional approval next year.
That means, if all goes as planned, veterinarians could begin prescribing the drug to eligible senior dogs in 2026.
For owners of large and giant breed dogs, the drug that matters most remains further down the pipeline.
LOY-001 and LOY-003 are targeting the breeds with the shortest lifespans and therefore the greatest potential benefit, but they face longer paths to approval because the evidence base is still being built.
In the meantime, the STAY study continues to follow its 1,300 enrolled dogs.
Every passing month produces more data on whether the pill being given to half of those dogs is genuinely doing what the biology predicts it should.
Every dog owner who has ever watched a beloved companion slow down, grey at the muzzle, struggle to climb the stairs that once posed no challenge, knows what is at stake.
The average dog gives everything it has for a decade or so.
Science is now asking, seriously and with rigorous clinical evidence behind the question, whether that decade can become a decade and a half.
Whether the tail wag at the door can last a few more years.
Whether goodbye can come a little later.
For the first time, the answer might be yes.
What Happens After Approval
LOY-002 is not on shelves yet, but the momentum is real and the timeline is tightening.
Loyal expects to complete the final major technical section, the manufacturing review, and apply for expanded conditional approval in 2027, with full approval to follow after the STAY study wraps up.
That means the window for dog owners is closer than most people realize.
If the manufacturing review goes smoothly, your veterinarian could be prescribing this drug within the next couple of years.
For millions of households with aging dogs, that is not an abstract scientific milestone.
It is the difference between nine more good years and eleven.
The expanded conditional approval pathway is worth understanding here, because it is not a shortcut.
It is a regulatory route specifically designed for innovative therapies that address unmet medical needs, allowing them to reach patients sooner while long-term trial data continues to accumulate.
LOY-002 would arrive on that basis, meaning vets would prescribe it before the STAY study’s full four-year data is in.
Loyal has worked to evaluate the safety of the drug under varied and realistic conditions of use, testing it in dogs with many of the health conditions and medical treatments that senior dogs commonly experience.
That is a meaningful distinction for a preventive drug.
Unlike a treatment given to a sick dog with nothing to lose, this pill would be given to a generally healthy senior dog, which means the safety bar has to be exceptionally high.
No clinically significant adverse events were observed even at doses five times the intended strength.
That is the kind of margin that gives veterinarians and dog owners genuine confidence.
Here Is What Most People Are Getting Wrong
The assumption most dog owners make when they first hear about LOY-002 is that this is a niche product.
A luxury drug for wealthy pet owners who want a few extra months with a beloved companion.
Understandable assumption.
Wrong one.
The deeper story is about what dogs represent to science, not just to their owners.
Dogs share our homes, diets, and environmental exposures, and they develop many of the same age-related diseases, making them a genuinely powerful real-world testing ground for interventions that would take decades to evaluate in human clinical trials.
Think about what that actually means.
A human longevity drug trial would need 30 to 40 years of follow-up before researchers could definitively say whether it extended life.
No pharmaceutical company, no matter how well funded, is going to run that trial.
Dogs solve that problem.
Their shorter life expectancy provides a unique opportunity for an accelerated timeline to test interventions that might extend healthy lifespan, compressing decades of data collection into a fraction of the time.
Every dog enrolled in STAY or TRIAD is doing double duty.
It is a family pet that might live longer and healthier because of its participation.
It is also a scientific instrument generating data that could eventually inform how humans manage their own aging bodies.
Dogs experience many of the age-related cognitive, sensory, neuropathologic and mobility changes that are common in older humans, which makes research into canine health mutually beneficial.
This is not peripheral research.
It is the front line.
The Rapamycin Angle: A Drug Already In Your Medicine Cabinet
While Loyal’s LOY-002 is the drug closest to reaching veterinary clinics, the parallel story running through the Dog Aging Project is just as compelling.
Rapamycin, also known as sirolimus and sold under the brand name Rapamune, works by inhibiting the mTOR pathway, which regulates metabolism and growth, producing effects similar to what happens in people who practice intermittent fasting.
It already exists.
It is already approved for human use.
Doctors have been prescribing it to organ transplant patients for decades.
The question the TRIAD trial is now seriously asking is whether this same drug, given in very low doses, can slow the aging process in a living, breathing, real-world animal.
The primary endpoint of the TRIAD trial is lifespan itself, and the trial has been designed with sufficient statistical power to detect a nine percent change in how long dogs live.
Nine percent may not sound dramatic.
For a dog expected to live 11 years, that is almost another year.
For a human expected to live 80 years, scaled proportionally, that is more than seven years.
The TRIAD study is slated to conclude in November 2029, and researchers are aiming to finish enrolling participants by the end of this year to initiate medication by spring 2026.
The results, when they arrive, will matter far beyond dog parks and veterinary waiting rooms.
The Funding Picture and What It Tells You
Science this ambitious does not run on goodwill alone.
Loyal has raised over $150 million in total investment since founding the company in 2019, including a $22 million B-2 round from investors including Valor Equity Partners and Collaborative Fund.
That is a serious amount of money flowing into what used to be considered fringe territory.
It signals that longevity science, at least in veterinary medicine, has crossed from speculative to investable.
The Dog Aging Project received a $7 million grant from the National Institutes of Health to expand the TRIAD trial, aiming to grow the number of participating dogs from 170 to 580 across new locations throughout the country.
Federal funding and private venture capital are now both pointed at the same question.
That convergence matters.
It means the science is being taken seriously at the highest levels, not just by dog lovers, but by institutions that have to justify every dollar they allocate.
What Dog Owners Can Do Right Now
If you have a senior dog aged 10 or older, weighing at least 14 pounds, LOY-002 is not yet something your vet can prescribe.
But the STAY trial is still gathering long-term data, and its findings will be the bedrock of full FDA approval.
If you have a larger dog aged 7 or older weighing at least 44 pounds, your dog may be eligible to participate in the TRIAD rapamycin trial through the Dog Aging Project.
Participation is free.
All examination costs and study medication are covered.
And your dog’s data would contribute directly to the most important aging research happening in veterinary science today.
For owners of large and giant breeds specifically, the drugs with the most potential benefit are LOY-001 and LOY-003, both targeting the IGF-1 mechanism responsible for the shortened lifespans of Great Danes, Bernese Mountain Dogs, and similar breeds.
Those products are further from approval, but they are actively in development.
The Bigger Question Aging Science Is Now Asking
For a long time, medicine treated aging as a backdrop, not a disease.
Doctors addressed cancer, or heart failure, or kidney disease.
Nobody addressed the underlying biological process that made all of those conditions more likely to happen in the first place.
What Loyal is attempting is fundamentally different: treating aging itself as the primary condition, targeting the biological processes that make every other age-related disease possible.
If LOY-002 is ultimately approved by the FDA, it would be the first drug approval for lifespan extension in any species.
That sentence should stop you for a moment.
Not the first dog drug.
Not the first veterinary drug.
The first drug of its kind, for any living creature, ever approved by a major regulatory body.
The implications ripple outward from there.
If you can slow aging in a dog, you have proof of concept for slowing aging in general.
You have regulatory precedent.
You have a template.
And then the question that has haunted medicine for centuries, the one that sounds like science fiction right up until it doesn’t, starts to feel a little more like a research agenda.
Dogs gave us loyalty, companionship, and unconditional love for thousands of years.
They may be about to give us something else entirely.
A map for how to age better.
References and sources:
Crossley KC. Second drug for canine healthy lifespan extension receives FDA support. dvm360. February 26, 2025. Accessed January 13, 2026. https://www.dvm360.com/view/second-drug-for-canine-healthy-lifespan-extension-receives-fda-support
Crossley KC. Clinical trial for longevity drug meets goal of enrolling 1000 dogs. dvm360. April 14, 2025. Accessed January 13, 2026. https://www.dvm360.com/view/clinical-trial-for-longevity-drug-meets-goal-of-enrolling-1000-dogs
Loyal FDA Safety Acceptance January 2026
